AFT Pharmaceuticals Secures FDA Tentative Approval for Scomara Cream; US Launch Postponed Until 2029

FDA Tentative Approval Confirms Scomara’s Development Success for AFT Pharmaceuticals

AFT Pharmaceuticals announced the US FDA’s tentative approval of Scomara (rapamycin 0.5% cream) for treating Facial Angiofibromas in Tuberous Sclerosis, a rare facial skin condition. The FDA’s comprehensive evaluation of quality, efficacy, and safety data led to tentative approval of product labelling and claims. This milestone validates AFT’s development strategy targeting a rare disease with significant unmet medical needs.

The tentative approval indicates Scomara meets FDA standards for quality, efficacy, and safety, positioning it for future market entry. However, commercial launch timing is constrained by existing regulatory limitations. Managing Director Dr Hartley Atkinson expressed satisfaction with the tentative approval but acknowledged disappointment over the delayed US launch timeline.

Orphan Drug Exclusivity Delays US Launch Until March 2029

The FDA granted orphan exclusivity to a competing product in 2022, providing seven years of market protection expiring on 22 March 2029. Under US orphan drug regulations, no other application for the same drug and indication can be approved during this period. Consequently, AFT cannot launch Scomara in the US until at least that date, causing a minimum three-year delay from tentative approval. Orphan exclusivity incentivizes rare disease drug development but restricts competing therapies’ market access.

This exclusivity applies solely to the US market and does not affect other global jurisdictions. AFT management views the delayed US launch as disappointing but regards the tentative approval as a catalyst to develop new markets outside the US where orphan exclusivity does not apply and where AFT has direct operations.

Scomara’s Competitive Edge in Canada, Australia, New Zealand, and Asia

The FDA’s tentative approval supports regulatory submissions in key markets without orphan exclusivity restrictions, including Canada, Australia, New Zealand, and several Asian countries where AFT operates directly or via established distributors. This approval is expected to facilitate regulatory processes and enable market entry.

Scomara offers significant competitive benefits over the existing orphan product outside the US, requiring only once-daily application and ambient temperature storage, unlike the competitor’s twice-daily dosing and refrigeration needs. These advantages improve patient convenience and adherence, enhancing clinical and commercial outcomes. AFT highlights these factors as favorable for market development beyond the US.

Market Size for Facial Angiofibromas in Tuberous Sclerosis

Facial Angiofibromas in Tuberous Sclerosis affects an estimated 15,000 to 30,000 patients in the US, defining a measurable addressable market. Tuberous Sclerosis Complex is a rare genetic disorder causing benign tumors, with facial angiofibromas significantly impacting patient quality of life. The orphan disease classification underpins regulatory incentives and exclusivity.

Patient populations with FA in TSC also exist in Canada, Australia, New Zealand, and Asian markets where AFT operates, though specific numbers were not disclosed. The global prevalence suggests meaningful opportunities in these regions. AFT’s direct presence facilitates targeted marketing to dermatology specialists, genetic clinics, and patient advocacy groups familiar with rare disease care.

AFT Pharmaceuticals’ Business Model and Global Reach

AFT Pharmaceuticals is a New Zealand-based multinational developing, marketing, and distributing a diverse pharmaceutical portfolio across OTC, prescription, and hospital channels. Its products include proprietary, in-licensed, patented, branded, and generic drugs. The company’s primary markets include Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, the European Union (excluding Ireland), and the UK, with out-licensing to distributors in over 125 countries.

This diversified geographic and channel approach provides multiple revenue streams and reduces reliance on any single market or product. Adding rare disease treatment Scomara complements AFT’s broader portfolio. Established distribution infrastructure in Australia, New Zealand, Canada, and Asia offers operational advantages for Scomara’s commercialisation outside the US. AFT’s regulatory expertise supports navigating orphan drug approvals globally.

Financial Structure and Impact of Scomara Approval

AFT receives 65% of global earnings from Scomara after development cost recovery, with 35% allocated to the minority owner of AFT Orphan Pharmaceuticals. Additionally, AFT earns a separate royalty for proprietary technology use in the product, payable before profit sharing. This structure ensures revenue from both commercial success and technology contributions.

No Scomara revenue is forecast in AFT’s FY27 budget, reflecting conservative planning given the time required for regulatory approvals and market development outside the US. The tentative approval does not affect FY27 financial guidance. However, non-US market opportunities position Scomara for potential significant future revenue following successful approvals and launches in Canada, Australia, New Zealand, and Asia.

Regulatory Strategy for Non-US Market Approvals

The FDA’s tentative approval lays a foundation for regulatory submissions in jurisdictions without orphan exclusivity barriers. Agencies in Canada, Australia, New Zealand, and Asia often consider FDA decisions as supportive evidence during their evaluations. AFT plans to leverage this approval to streamline international regulatory processes.

Each market requires independent submissions and reviews, but FDA validation of quality, efficacy, and safety strengthens applications. Approval timelines will vary by jurisdiction based on regulatory requirements and review capacity. AFT’s direct operations in these regions facilitate direct engagement with authorities, potentially accelerating approvals and ensuring consistent regulatory strategies.

Strategic Significance of Scomara Approval for AFT’s Rare Disease Expansion

The FDA’s tentative approval underscores AFT’s commitment to developing rare disease therapies addressing unmet medical needs. Orphan drug development involves smaller patient populations, specialized regulatory pathways, and incentives to support investment. AFT’s progress with Scomara demonstrates its capability to manage orphan drug programs and complex regulatory landscapes, enhancing its credibility in rare disease therapeutics and opening prospects for further rare disease product acquisitions or licensing.

AFT views the tentative approval as a positive driver for expanding into significant new markets outside the US. The orphan exclusivity in the US is seen as a temporary constraint redirecting focus to markets with fewer restrictions. The company’s existing infrastructure in Canada, Australia, New Zealand, and Asia provides a strong base for Scomara’s growth. Success in these regions could strengthen AFT’s competitive position in rare diseases and support future product development or acquisition initiatives.